Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1982 Jan;79(2):640–644. doi: 10.1073/pnas.79.2.640

Gut-mediated hypercalcemia in rabbits bearing VX2 carcinoma: new mechanism for tumor-induced hypercalcemia.

S H Doppelt, D M Slovik, R M Neer, J Nolan, R M Zusman, J T Potts Jr
PMCID: PMC345802  PMID: 6210910

Abstract

The VX2 carcinoma-bearing rabbit is an animal model for tumor-induced hypercalcemia, thought to be due to increased bone destruction effected by prostaglandin E2. The present experiments suggest that the pathophysiology of the hypercalcemia differs from that previously proposed. Tumor was transplanted intramuscularly into 2.5- to 3-kg male New Zealand White rabbits, which were conditioned to a 1.5% calcium diet and treated with daily subcutaneous injections of dichloromethane diphosphonate (10 mg . kg-1 . day-1), a potent inhibitor of bone resorption, or 0.9% NaCl (2 ml . kg-1 . day -1). The diphosphonate had no significant effect on plasma Ca2+ in either group. After day 31, half the animals of each group were fed a calcium-free diet. This normalized the plasma Ca2+ in each VX2-bearing rabbit within 3 to 4 days but had little effect in control rabbits. In a second series of experiments, VX2-bearing rabbits maintained on standard rabbit chow were treated for 11 days with parenteral indomethacin (30--60 mg/day) or 0.9% NaCl. Although indomethacin normalized the markedly elevated urinary excretion of prostaglandin E2, both treatment groups became severely hypercalcemic. Dietary calcium restriction promptly restored to normal the plasma Ca2+ concentration. In a third series of experiments, rabbits were fed standard rabbit chow and treated with oral indomethacin (40 mg/day) while control-rabbits were pair fed in identical chow. Transplantation of VX2 tumor into both groups caused hypercalcemia. We conclude that the hypercalcemia produced by this tumor strain is indomethacin resistant and dependent on an increase in gastrointestinal calcium absorption, not on skeletal calcium mobilization.

Full text

PDF
640

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caro J. F., Besarab A., Flynn J. T. Prostaglandin E and hypercalcemia in breast carcinoma: only a tumor marker? A need for perspective. Am J Med. 1979 Feb;66(2):337–341. doi: 10.1016/0002-9343(79)90561-8. [DOI] [PubMed] [Google Scholar]
  2. Doppelt S. H., Neer R. M., Potts J. T., Jr Human parathyroid hormone 1-34-mediated hypercalcemia in a rat model, and its inhibition by dichloromethane diphosphonate. Calcif Tissue Int. 1981;33(6):649–654. doi: 10.1007/BF02409503. [DOI] [PubMed] [Google Scholar]
  3. Franklin R. B., Tashjian A. H., Jr Intravenous infusion of prostaglandin E2 raises plasma calcium concentration in the rat. Endocrinology. 1975 Jul;97(1):240–243. doi: 10.1210/endo-97-1-240. [DOI] [PubMed] [Google Scholar]
  4. Frölich J. C., Wilson T. W., Sweetman B. J., Smigel M., Nies A. S., Carr K., Watson J. T., Oates J. A. Urinary prostaglandins. Identification and origin. J Clin Invest. 1975 Apr;55(4):763–770. doi: 10.1172/JCI107987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Galasko C. S., Bennett A. Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins. Nature. 1976 Oct 7;263(5577):508–510. doi: 10.1038/263508a0. [DOI] [PubMed] [Google Scholar]
  6. Galasko C. S., Rawlins R., Bennett A. Timing of indomethacin in the control of prostaglandins, osteoclasts and bone destruction produced by VX2 carcinoma in rabbits. Br J Cancer. 1979 Sep;40(3):360–364. doi: 10.1038/bjc.1979.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Galasko C. S., Samuel A. W., Rushton S., Lacey E. The effect of prostaglandin synthesis inhibitors and diphosphonates on tumour-mediated osteolysis. Br J Surg. 1980 Jul;67(7):493–496. doi: 10.1002/bjs.1800670714. [DOI] [PubMed] [Google Scholar]
  8. Klein D. C., Raisz L. G. Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology. 1970 Jun;86(6):1436–1440. doi: 10.1210/endo-86-6-1436. [DOI] [PubMed] [Google Scholar]
  9. MYERS W. P. Hypercalcemia in neoplastic disease. Arch Surg. 1960 Feb;80:308–318. doi: 10.1001/archsurg.1960.01290190128024. [DOI] [PubMed] [Google Scholar]
  10. Meunier P. J., Chapuy M. C., Alexandre C., Bressot C., Edouard C., Vignon C., Mathieu L., Trechsel U. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet. 1979 Sep 8;2(8141):489–492. doi: 10.1016/s0140-6736(79)91551-4. [DOI] [PubMed] [Google Scholar]
  11. Robertson R. P., Baylink D. J. Hypercalcemia induced by prostaglandin E2 in thyroparathyroidectomized but not intact rats. Prostaglandins. 1977 Jun;13(6):1141–1145. doi: 10.1016/0090-6980(77)90140-x. [DOI] [PubMed] [Google Scholar]
  12. Russell R. G., Kislig A. M., Casey P. A., Fleisch H., Thornton J., Schenk R., Williams D. A. Effect of diphosphonates and calcitonin on the chemistry and quantitative histology of rat bone. Calcif Tissue Res. 1973 Mar 12;11(3):179–195. doi: 10.1007/BF02547218. [DOI] [PubMed] [Google Scholar]
  13. Seyberth H. W., Hubbard W. C., Oelz O., Sweetman B. J., Watson J. T., Oates J. A. Prostaglandin-mediated hypercalcemia in the VX2 carcinoma-bearing rabbit. Prostaglandins. 1977 Aug;14(2):319–331. doi: 10.1016/0090-6980(77)90177-0. [DOI] [PubMed] [Google Scholar]
  14. Seyberth H. W., Segre G. V., Morgan J. L., Sweetman B. J., Potts J. T., Jr, Oates J. A. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med. 1975 Dec 18;293(25):1278–1283. doi: 10.1056/NEJM197512182932502. [DOI] [PubMed] [Google Scholar]
  15. Siris E. S., Sherman W. H., Baquiran D. C., Schlatterer J. P., Osserman E. F., Canfield R. E. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med. 1980 Feb 7;302(6):310–315. doi: 10.1056/NEJM198002073020602. [DOI] [PubMed] [Google Scholar]
  16. Trechsel U., Taylor C. M., Bonjour J. P., Fleisch H. Influence of prostaglandins and of cyclic nucleotides on the metabolism of 25-hydroxyvitamin D3 in primary chick kidney cell culture. Biochem Biophys Res Commun. 1980 Apr 29;93(4):1210–1216. doi: 10.1016/0006-291x(80)90618-x. [DOI] [PubMed] [Google Scholar]
  17. Vanderwiel C. J., Talmage R. V. Comparison of the effects of prostaglandin E2 and parathyroid hormone on plasma calcium concentration and osteoclast function. Endocrinology. 1979 Sep;105(3):588–594. doi: 10.1210/endo-105-3-588. [DOI] [PubMed] [Google Scholar]
  18. Vane J. R. The release and fate of vaso-active hormones in the circulation. Br J Pharmacol. 1969 Feb;35(2):209–242. doi: 10.1111/j.1476-5381.1969.tb07982.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Voelkel E. F., Tashjian A. H., Jr, Franklin R., Wasserman E., Levine L. Hypercalcemia and tumor-prostaglandins: the VX2 carcinoma model in the rabbit. Metabolism. 1975 Aug;24(8):973–986. doi: 10.1016/0026-0495(75)90089-x. [DOI] [PubMed] [Google Scholar]
  20. WILSON J. R., MERRICK H., VOGEL S. D., WOODWARD E. R. HYPERPARATHYROID-LIKE STATE IN RABBITS WITH THE VX-2 CARCINOMA: FURTHER STUDIES. Am Surg. 1965 Feb;31:144–152. [PubMed] [Google Scholar]
  21. Young D. M., Fioravanti J. L., Prieur D. J., Ward J. M. Hypercalcemic VX-2 carcinoma in rabbits: a clinicopathologic study. Lab Invest. 1976 Jul;35(1):30–46. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES